Low density lipoprotein receptor-related protein and apolipoprotein E expression is altered in schizophrenia
No Preview Available
Citations
Scopus:
Altmetric:
Altmetric::
Associated Records
Authors
File Licence
Editors
Date
2010-12-01
Source Title
Frontiers in Psychiatry
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Media SA
Melbourne Authors
Affiliation
Melbourne Veterinary School
Florey Department of Neuroscience and Mental Health
Florey Department of Neuroscience and Mental Health
Document Type
Journal Article
Subject Code
Citation
Gibbons, A. S., Thomas, E. A., Scarr, E. & Dean, B. (2010). Low density lipoprotein receptor-related protein and apolipoprotein E expression is altered in schizophrenia. Frontiers in Psychiatry, 1 (JUL), pp.19-. https://doi.org/10.3389/fpsyt.2010.00019.
Access Status
Access this item via the Open Access location
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
Our recent microarray study reported altered mRNA expression of several low density lipoprotein receptor-related proteins (LRP) associated with the first 4 years following diagnosis with schizophrenia. Whilst this finding is novel, apolipoprotein E (APOE), which mediates its activity through LRPs, has been reported by several studies to be altered in brains of subjects with schizophrenia. We used qPCR to measure the expression of LRP2, LRP4, LRP6, LRP8, LRP10 and LRP12 mRNA in Brodmann's area (BA) 46 of the dorsolateral prefrontal cortex in 15 subjects with short duration of illness schizophrenia (SDS) and 15 pair matched controls. We also used Western blotting to measure APOE protein expression in BA46 from these subjects. Amongst the LRPs examined, LRP10 expression was significantly increased (P = 0.03) and LRP12 was significantly decreased (P < 0.01) in SDS. APOE protein expression was also increased in SDS (P = 0.01). No other marker examined in this study was altered with diagnosis. Our data supports a role for distinct members of the LRP family in the pathology of schizophrenia and adds weight to the hypothesis that aberrant apolipoprotein signaling is involved in the early stages of schizophrenia.